Landscape Dashboard

Analyze the gene-editing trial field

Scan API-backed trial records by phase, status, disease, editing method, delivery method, geography, and recent updates.

Loading dashboard data...

Search trials

Registry matches

8

ClinicalTrials.gov result count

Loaded sample

8

Records analyzed below

Recruiting

4

Open or actively enrolling

In vivo

1

Delivered directly in body

Trials by phase

Where studies sit in the clinical pipeline.

Phase 13
Phase 1/22
Phase 22
Phase 31

Trials by status

Recruiting and active trial availability.

Recruiting4
Active2
Completed1
Not yet recruiting1

Editing methods

Modality breakdown across selected records.

CRISPR-Cas95
Base Editing2
Prime Editing1

Delivery methods

How edited therapies are delivered.

Ex vivo5
Lipid nanoparticle2
In vivo1

Disease areas

Conditions represented in the current trial set.

Sickle Cell Disease2
Acute Lymphoblastic Leukemia1
Beta Thalassemia1
Genetic Liver Disease1
Inherited Retinal Disease1
Solid Tumor1
Transthyretin Amyloidosis1

Geographic footprint

High-level location grouping for trial records.

United States6
International1
United Kingdom1

Landscape readout

Delivery patterns are split across modalities.

The loaded sample separates cell-based ex vivo programs from direct in vivo approaches such as AAV and lipid nanoparticle delivery.

5

ex vivo records

3

delivery categories

Recently updated trials

Most recent records in the current local trial set.

NCT IDTrialStatusUpdated
NCT05687110

Base Edited Hematopoietic Stem Cells for Sickle Cell Disease

Sickle Cell Disease - HBG1/HBG2

Recruiting2026-05-10
NCT04925206

Autologous CRISPR-Edited T Cells for Relapsed Leukemia

Acute Lymphoblastic Leukemia - PDCD1

Recruiting2026-05-02
NCT06025084

In Vivo CRISPR Therapy for Transthyretin Amyloidosis

Transthyretin Amyloidosis - TTR

Recruiting2026-04-26
NCT03745287

CRISPR-Cas9 Therapy for Severe Sickle Cell Disease

Sickle Cell Disease - BCL11A

Recruiting2026-04-18
NCT04208529

CRISPR-Modified Immune Cells for Solid Tumors

Solid Tumor - TRAC

Active2026-04-07